Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

LONDON, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday its experimental next-generation obesity ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...